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BACKGROUND: Endometrial cancer incidence is increasing in industrialised countries. High body mass index (BMI, kgm
 2) is associated
with higher risk for disease. We wanted to investigate if BMI is related to clinico-pathological characteristics, hormone receptor status
in primary tumour, and disease outcome in endometrial cancer.
PATIENTS AND METHODS: In total, 1129 women primarily treated for endometrial carcinoma at Haukeland University Hospital during
1981–2009 were studied. Body mass index was available for 949 patients and related to comprehensive clinical and histopathological
data, hormone receptor status in tumour, treatment, and follow-up.
RESULTS: High BMI was significantly associated with low International Federation of Gynaecology and Obstetrics (FIGO) stage,
endometrioid histology, low/intermediate grade, and high level of progesterone receptor (PR) mRNA by qPCR (n¼150; P¼0.02)
and protein expression by immunohistochemistry (n¼433; P¼0.003). In contrast, oestrogen receptor (ERa) status was not
associated with BMI. Overweight/obese women had significantly better disease-specific survival (DSS) than normal/underweight
women in univariate analysis (P¼0.035). In multivariate analysis of DSS adjusting for age, FIGO stage, histological subtype, and grade,
BMI showed no independent prognostic impact.
CONCLUSION: High BMI was significantly associated with markers of non-aggressive disease and positive PR status in a large population-
based study of endometrial carcinoma. Women with high BMI had significantly better prognosis in univariate analysis of DSS, an effect
that disappeared in multivariate analysis adjusting for established prognostic markers. The role of PR in endometrial carcinogenesis
needs to be further studied.
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Endometrial cancer is the most common gynaecological mali-
gnancy in industrialised countries (Parkin et al, 2005), and the
incidence has been increasing over the last decades (Cancer
Registry of Norway, 2009). Obesity is a known risk factor for
disease development with a higher risk with increasing body mass
index (BMI, kgm
 2) (Schouten et al, 2004; Bjorge et al, 2007). It
has recently been shown that morbidly obese women (BMIX40)
have a six-fold increase in risk of disease development (Lindemann
et al, 2008). This is presumably related to unopposed oestrogen
exposure. After menopause, the ovaries and adrenal glands
continue to produce androstenedione, which is converted to
oestrone in adipose tissue by the aromatase enzyme. This weaker
oestrogen may stimulate chronic endometrial proliferation and
cancer development after menopause (Kaaks et al, 2002). Tumours
arising in such hyper-oestrogenic environment are typically type I
endometrial carcinomas, characterized by endometrioid histology,
low grade, hormone receptor-positive status, and good prognosis.
In contrast, tumours of type II are typically not oestrogen driven,
of non-endometrioid histology, high grade, with loss of hormone
receptors and poor prognosis (Bokhman, 1983; Amant et al, 2005).
However, the prognostic value of the distinction between type I
and type II endometrial cancer is limited, as up to 20% of type I
endometrial cancers recur and 50% of type II cancers do not
(Engelsen et al, 2009). Diagnostic accuracy and reproducibility of
histological subtyping is a challenge. Therefore, there is need for
new prognostic markers. Even though it is well established that
obesity gives higher risk for endometrial cancer, studies relating
BMI to clinical and histopathological markers and survival are
scarce, and partly contradictive (Anderson et al, 1996; Duska et al,
2001; von Gruenigen et al, 2006; Temkin et al, 2007; Munstedt et al,
2008; Jeong et al, 2010). In particular, no previous studies have
identified molecular markers for hormone receptor status in the
tumour tissue related to BMI.
On this background, we have investigated the relationship
between BMI and a large panel of clinical and histopathological
Received 2 November 2010; revised 24 January 2011; accepted
26 January 2011; published online 22 February 2011
*Correspondence: Dr H Salvesen; E-mail: helga.salvesen@uib.no
British Journal of Cancer (2011) 104, 921–926
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdata, hormone receptor status in primary tumours, and disease
outcome in a large population-based endometrial carcinoma series.
PATIENTS AND METHODS
Patient series
The patient series include 1129 women primarily treated for
endometrial carcinoma at Haukeland University Hospital during
the period 1981 through 2009. This is the referral hospital for
Hordaland county, with B475000 inhabitants, representing about
10% of the Norwegian population (SSB, 2010). The endometrial
cancer incidence rate and prognosis in this area are similar to data
for the total population (Cancer Registry of Norway, 2009).
Information concerning height, weight, age, menopausal status,
International Federation of Gynaecology and Obstetrics (FIGO)
stage, histological subtype and grade, treatment, and follow-up was
collected by review of the medical records and through
correspondence with the primary physicians. In all, 91% of the
women underwent hysterectomy with bilateral salpingo-oophor-
ectomy as primary treatment and were classified according to the
FIGO 1988 criteria (Mikuta, 1993). If surgical treatment was
contraindicated, the staging was based on the available informa-
tion from curettage results, clinical examination, chest X-ray, and
abdomino-pelvic CT.
Follow-up time was defined as the time interval between date of
primary diagnosis and date of death or last follow-up. The median
follow-up time was 4.9 years (range 0.01–23.2). In all, 223 patients
(20%) died from endometrial carcinoma during the follow-up
period, while 207 (18%) died from other causes. These data were
cross-checked with information from the Cancer Registry of
Norway and the Register of Statistics Norway. Last follow-up was
20 December 2009.
Body mass index was calculated as weight (kg) divided by
squared height (m
2), both measured at the time of diagnosis. These
data were available for 949 patients (84%). For the statistical
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Figure 1 Distribution of BMI for endometrial carcinoma patients treated
in one defined region in Norway (Hordaland county) in the periods
1981–1990, 1991–2000, and 2001–2009. Median BMI and range
increase significantly from 25.3 (16.9–44.5) to 26.7 (15.8–50.5) and 26.9
(14.7–73.0) for the time periods studied, P¼0.002 (Kruskal–Wallis test).
¼minor outliers and ¼major outliers.
Table 1 Distribution of clinico-pathological factors in 949 patients with endometrial carcinoma according to body mass index (BMI)
Variable Total no. of patients Median BMI Lean (%) Normal (%) Overweight (%) Obese (%) P-value
a
Age, quartiles
b 949 0.002
1 (age 26–58) 25.6 5 (2) 109 (45) 66 (27) 65 (27)
2 (age 58–66) 27.1 8 (3) 76 (32) 82 (34) 73 (31)
3 (age 66–74) 27.3 2 (1) 76 (31) 91 (37) 76 (31)
4 (age 74–95) 25.1 8 (4) 97 (44) 70 (32) 45 (21)
Menopause
c 949 0.116
Pre/peri 26.1 1 (1) 54 (44) 31 (25) 38 (31)
Post 26.4 22 (3) 304 (37) 278 (34) 221 (27)
FIGO stage 949 o0.0001
I 26.6 10 (2) 246 (36) 224 (33) 197 (29)
II 27.3 3 (3) 30 (29) 45 (44) 26 (25)
III 24.4 7 (6) 55 (49) 30 (27) 21 (19)
IV 24.0 3 (6) 27 (49) 10 (18) 15 (27)
Histological subtype 949
Endometrioid 26.6 16 (2) 297 (37) 269 (33) 229 (28) 0.030
Non-endometrioid 25.1 7 (5) 61 (44) 40 (29) 30 (22)
Grade
d 905 0.174
1 or 2 26.7 14 (2) 242 (36) 224 (34) 188 (28)
3 25.7 9 (4) 99 (42) 71 (30) 58 (25)
PR 433 0.003
e
Positive 26.9
Negative 25.5
ER 437 0.08
e
Positive 26.7
Negative 25.5
Abbreviation: FIGO¼International Federation of Gynaecology and Obstetrics.
aw
2-test when no other specified.
bTruncated to closest integer.
cMenopausal status was
determined based on the information from the patient records.
dData missing for 44 patients.
eMann–Whitney U-test.
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sanalyses on BMI we used the quartiles for the data set as cut points,
as well as the established WHO classification system; BMI under
18.5 (underweight), between 18.5 and 24.9 (normal), between 25
and 29.9 (overweight), and 430 (obese). Height and weight of
outliners (BMIo15 and BMI450, n¼7) was double-checked. All
analyses were also performed excluding these; this did not affect
any of the conclusions.
Immunohistochemistry
Formalin-fixed paraffin-embedded tumour specimens were
mounted in tissue microarrays (TMAs) as previously described
(Hoos et al, 2001; Stefansson et al, 2004). Briefly, TMA was
constructed by identifying the area of highest tumour grade on
HE-stained slides, followed by punching out three tissue cylinders
from the selected areas of the donor block and mounting these into
a recipient paraffin block using a custom-made precision
instrument (Beecher Instruments, Silver Spring, MD, USA).
Immunohistochemical staining for receptor status was assessed
for oestrogen- and progesterone receptors (ERa and PR) and
available for 437 and 433 patients for ERa and PR, respectively
(38% of study population). The method for immunohistochemical
staining was as previously described, using the lower quartile to
define receptor loss (Engelsen et al, 2008b).
qPCR analysis
From a subset of 150 patients (13%), fresh frozen tumour tissue
was collected prospectively and was available for mRNA analysis in
parallel with the immunohistochemical staining. Total RNA was
extracted using the RNeasy kit (Qiagen, Hilden, Germany), with
quality control and method for data processing as previously
reported (Engelsen et al, 2008a; Salvesen et al, 2009). mRNA
expression levels in tumours for ERa and PR were investigated by
qPCR using the TaqMan Low Density Array technique (Engelsen
et al, 2008a).
Statistical methods
Body mass index in WHO categories was applied to assess the
distribution of various clinico-pathological variables, using the
Pearson’s w
2-test. Hormone receptor status in primary tumour in
relation to BMI was assessed by the Mann–Whitney U-test.
Univariate survival analyses for disease-specific survival (DSS) and
overall survival (OS) were performed using the Kaplan–Meier
method (log-rank test). The Cox proportional hazard regression
analysis was applied to evaluate the prognostic impact of BMI
adjusted for the established prognostic markers in endometrial
carcinoma. We compared the distribution of clinico-pathological
variables and prognosis for patients with available data for BMI to
patients where these data were missing (16%). Women lacking
BMI data were older, with median age 69.3 years compared with
65.2 years for the group where BMI was registered, P¼0.004
(Mann–Whitney U-test). No other significant differences were
identified. The statistical software PASWStatistics18.0 was used for
data analyses (SPSS Inc., Chicago, IL, USA).
The study was approved by the IRB (NSD 15501, REK III nr
052.01).
RESULTS
High BMI associates with clinico-pathological markers for
non-aggressive disease
The median BMI at diagnosis was 26.4 (range 14.7–73.0), with
significantly increasing BMI throughout the study period,
P¼0.002 (Figure 1). There was a significant association between
BMI and patient age at diagnosis, FIGO stage, and histological
subtype, as shown in Table 1. The proportion of patients with
BMIo25 was larger in the lower and upper age quartiles compared
with BMIX25, whereas there was a tendency for the patients of the
middle age quartiles to be overweight or obese. The proportion of
normal/lean patients was larger for FIGO stages III and IV
compared with FIGO stages I and II. High BMI was also associated
with endometrioid histology. There was no significant association
between BMI and menopausal status nor BMI and grade. Also,
there was no significant difference in number of performed
Table 2 Univariate survival analysis (Kaplan–Meier estimates) according
to clinico-pathological factors and BMI in 1129 endometrial carcinoma
patients
Variable
No. of patients
(no. of deaths)
a
5-year
survival
P
(log-rank)
Age, quartiles
b o0.0001
1 (age 27–58) 282 (17) 94.5
2 (age 58–66) 282 (44) 84.4
3 (age 66–74) 283 (73) 73.8
4 (age 74–94) 282 (89) 63.8
Sum 1129
Menopausal status o0.0001
Pre/peri 145 (13) 93.9
Post 983 (87) 77.1
Sum
c 1128
FIGO stage o0.0001
I 812 (79) 90.8
II 119 (27) 74.2
III 132 (68) 39.4
IV 65 (48) 16.3
Sum
d 1128
Histological subtype o0.0001
Endometrioid 966 (146) 84.4
Non-endometrioid 163 (77) 46.8
Sum 1129
Grade o0.0001
1 345 (26) 92.0
2 454 (81) 82.6
3 283 (105) 56.9
Sum
e 1082
BMI WHO 0.066
f
Underweight (o18.5) 23 (7) 63.3
Normal (18.5–24.9) 358 (77) 77.0
Overweight (25–29.9) 309 (51) 81.9
Obese (X30) 259 (47) 81.1
Sum
g 949
BMI quartiles 0.096
f
1 (14.7–23.1) 237 (54) 75.3
2 (23.1–26.3) 240 (46) 79.1
3 (26.3–30.5) 236 (39) 81.3
4 (30.5–73.0) 236 (43) 81.4
Sum 949
BMI 2 groups
h 0.035
f
o25 381 (84) 76.3
X25 568 (98) 81.6
Sum 949
Abbreviations: BMI¼body mass index; FIGO¼International Federation of Gynae-
cology and Obstetrics; WHO¼World Health Organization.
aNumber of patients
varies due to missing data.
bTruncated to closest integer.
cData for menopausal status
missing for one patient.
dData for FIGO stage missing for one patient.
eData for grade
missing for 67 patients.
fP-value with linear trend test.
gData for BMI missing for 180
patients.
hEndometrioid carcinomas only: 5-year survival: BMIo25¼81.2%,
BMIX25¼85.6% (P¼0.134).
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more adjuvant therapy given to patients with BMIo25 (P¼0.06).
High BMI associates with positive PR status in tumour
When investigating biomarkers for receptor status in tumours
related to BMI we found that patients with PR-negative
tumours (by IHC) had lower median BMI compared with the
patients who had PR-positive tumours, median 25.5 vs 26.9,
respectively (P¼0.003, Mann–Whitney U-test). We did not find
any significant correlation between BMI and ERa status in tumours
(P¼0.08) (Table 1). To further validate this finding, we examined
a subset of 150 fresh frozen patient samples for
mRNA expression levels for hormone receptors by qPCR. This
confirmed a significantly higher mRNA expression level for
PR in patients with BMI425 compared with patients with lower
BMI (P¼0.02, Mann–Whitney U-test). For ERa, no such
association with BMI was observed for mRNA expression levels
(P¼0.21). Loss of ERa and PR (by IHC) was associated with
postmenopausal status (P¼0.01 and P¼0.006, respectively,
Pearson’s w
2-test).
BMI and prognosis
Univariate analysis The established clinico-pathological variables
showed, as expected, a highly significant impact on DSS, as listed in
Table 2. There was a trend towards better prognosis for patients with
higher BMI in univariate analysis (Table 2). Patients being
overweight/obese vs normal/underweight as defined by the WHO
had better DSS, with a 5-year survival of 82% for women with
BMIX25 compared with 76% for BMIo25 (P¼0.035; Figure 2A;
Table 2). For OS, we found that patients with BMIo25 had a 5-year
survival of 69% compared with 74% for patients with BMIX25
(P¼0.18; Figure 2B). In the OS analysis, we also see a pattern of
diminishing survival difference between the two BMI groups 410
years after diagnosis. This may relate to the higher risk of developing
other diseases for overweight women, being more important than
the risk for cancer-related deaths 410 years after diagnosis.
Multivariate analysis The survival effect of BMI observed in
univariate analysis for DSS disappeared when adjustment was
made for age at diagnosis (continuous variable), FIGO stage,
histological subtype, and grade in the Cox multivariate regression
analysis as listed in Table 3. Adjusted HR for BMIo25 vs X25 was
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Figure 2 Univariate survival plot by Kaplan–Meier for estimation of DSS (A) and OS (B) in patients with endometrial carcinoma related to BMI. The total
number of patients in each group is followed by number of deaths, given in parentheses; P-value based on the Mantel–Cox test.
Table 3 Survival analysis of 905 endometrial carcinoma patients based on the Cox proportional hazards model
Variable No. of patients (%) Unadjusted HR
a 95% CI P-value Adjusted HR 95% CI P-value
FIGO stage o0.0001 o0.0001
I 646 (71) 1.00 1.00
II 96 (11) 3.25 1.98–5.31 2.83 1.72–4.65
III 111 (12) 9.75 6.73–14.12 8.13 5.52–11.97
IV 52 (6) 32.60 21.10–50.35 24.41 14.80–40.26
Histological subtype o0.0001 0.08
Endometrioid 777 (86) 1.00 1.00
Non-endometrioid 128 (14) 4.76 3.44–6.57 1.49 0.95–2.32
Grade o0.0001 0.11
1 or 2 668 (74) 1.00 1.00
3 237 (26) 3.84 2.83–5.19 1.41 0.93–2.13
Age
b 904 (100) 1.06 1.04–1.07 o0.0001 1.05 1.03–1.06 o0.0001
BMI
c 0.04 0.65
o25 364 (40) 1.38 1.02–1.86 0.93 0.68–1.27
X25 541 (60) 1.00 1.00
Abbreviations: BMI¼body mass index; CI¼confidence interval; FIGO¼International Federation of Gynaecology and Obstetrics; HR¼hazard ratio.
aAnalyses based on patients
with complete information for all variables (n¼905).
bAge at primary operation, continuous variable with HR given per year.
cWhen including patients with endometrioid
histology only: adjusted HR for BMI was 1.07, 95% CI 0.73–1.55, P¼0.7.
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continuous variable in the same Cox model, we found a similar
insignificant HR for BMI of 1.01 (CI 0.98–1.04), and pattern for
the other variables with independent impact for FIGO stage and
age only. In contrast, when using OS as end point in the Cox
model, we found that BMI had independent impact on prognosis
when introduced as a continuous variable with an HR 1.02
(CI 1.00–1.04, P¼0.035). FIGO stage and age were also
independent predictors of prognosis (Po0.0001 for both), while
histology was of borderline significance (P¼0.053) and grade was
non-significant (P¼0.166).
DISCUSSION
To our knowledge, this is the most comprehensive study of clinico-
pathological variables to date. It is also the largest study to date
exploring the relationship between BMI and a large panel of
markers for tumour phenotype in endometrial carcinoma. The
large sample size with careful characterisation of FIGO stage,
histological subtype, and grade confers more accuracy to the
estimates for the independent prognostic impact of BMI compared
with smaller previous studies. Also, the fact that the patient series
studied was derived from a well-defined geographic region in
Norway, previously shown to be representative for the total
Norwegian population (Salvesen et al, 1999), suggests that the
findings may be representative for a Caucasian patient population
in general.
We found a positive association between high BMI and
favourable DSS in univariate analysis but not in multivariate
analysis. However, in multivariate analysis of OS, we found an
independent unfavourable prognostic impact of increasing BMI.
Previous studies exploring the effect of BMI on survival have
reported conflicting results, which may be due to sample sizes,
choice of cut point for BMI, outcome variables applied, and the
panel of clinico-pathological markers adjusted for in the multi-
variate analyses. Like the present study, several have reported a
trend towards better survival in the overweight compared with the
more slender women (Anderson et al, 1996; Temkin et al, 2007;
Munstedt et al, 2008). Others have concluded with no difference
(Jeong et al, 2010) and even poorer survival for women with higher
BMI (von Gruenigen et al, 2006). Disease-specific survival applied
in the present study is more likely to be accurate in detecting
deaths directly related to the disease studied. Previous studies,
mostly applying OS, may have underestimated the positive
biological impact of obesity, as obese women have increased risk
of dying from intercurrent disease (Anderson et al, 1996; Temkin
et al, 2007). Our findings that OS is less favourable for obese
women when adjusted for the standard clinico-pathological risk
factors may support this.
A limit of our study is that BMI is measured at the time of
diagnosis. This may lead to a bias, as aggressive cancers often are
associated with weight loss, cachexia, and anorexia (Keller 1993).
Hence, we may have underestimated the weight of patients
presenting with high stage cancers.
The rise in endometrial carcinoma incidence has been
associated with an epidemic of obesity and physical inactivity
(Amant et al, 2005). Unopposed oestrogen exposure leads to
endometrial hyperplasia, and increased risk of atypical hyperplasia
and type I endometrial cancer (Shang, 2006). The significance of
progesterone in controlling oestrogen-driven proliferation is
underlined by its efficacy in preventing endometrial cancer
(Kim and Chapman-Davis, 2010). Still, the molecular basis and
cross talk between hormone receptor pathways are poorly under-
stood (Kim and Chapman-Davis, 2010). In previous smaller
immunohistochemical studies (Duska et al, 2001; Gates et al,
2006), no significant relationship between hormone receptor status
and BMI was identified (n¼41 and n¼165, respectively). We found
that BMI was significantly linked to alterations in PR but not ERa
status in tumours, confirmed by two different techniques estimating
mRNA and protein levels for PR and ERa. The biological function of
PR may be altered by genetic variations. Interestingly, recent studies
have identified a single-nucleotide polymorphism in the gene
coding for the PR, which has been associated with increased risk for
endometrial carcinoma (Xu et al, 2009; O’Mara et al,2 0 1 0 ) .T h i s
support the complexity in the hormone receptor interactions related
to carcinogenesis and tumour development in endometrial cancer,
and further studies of these interactions are needed.
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